Marburg and Ebola virus infections elicit a muted inflammatory state in bats

Anitha D. Jayaprakash[1], Adam J. Ronk[2,3], Abhishek N. Prasad[2,3], Michael F. Covington[4], Kathryn R. Stein[8], Toni M. Schwarz[7], Saboor Hekmaty[8], Karla A. Fenton[3,5], Thomas W. Geisbert[3,5], Christopher F. Basler[6], Alexander Bukreyev[2,3,5]*, Ravi Sachidanandam[8] **

1 Girihlet Inc., Oakland, CA 94609

2 Department of Pathology, the University Texas Medical Branch, Galveston, Texas, United States of America

3 Galveston National Laboratory, the University of Texas Medical Branch, Galveston, Texas, United States of America

4 Amaryllis Nucleics, Oakland, CA 94609

5 Department Microbiology & Immunology, the University of Texas Medical Branch, Galveston, Texas, United States of America

6 Center for Microbial Pathogenesis, Institute for Biomedical Sciences, Georgia State University, Atlanta, GA 30303, USA

7 Department of Microbiology, Mount Sinai School of Medicine, New York, NY 10029

8 Department of Oncological Sciences, Mount Sinai School of Medicine, New York, NY 10029

Email for correspondence:

*Alexander Bukreyev, alexander.bukreyev@utmb.edu

**Ravi Sachidanandam, ravi.mssm@gmail.com

ABSTRACT

Background. The Marburg and Ebola filoviruses cause severe, often fatal, disease in humans and nonhuman primates but have only subclinical effects in bats, including Egyptian rousettes, a natural reservoir of Marburg virus. A fundamental question is why these viruses are highly pathogenic in humans but fail to cause disease in bats. A number of hypotheses have been proposed to explain this unique aspect of bat biology. We hypothesized that the response of bats to filoviruses is systemic, involving multiple interrelated processes, and that the difference in the responses to infection between bats in humans is due to evolutionarily divergent genes.

Results. To understand how bats resist disease, we challenged two cohorts of Egyptian rousette bats with Marburg virus or Ebola virus and employed RNA-Seq to profile tissue-specific transcriptomic signatures. While we have found the viruses primarily in the liver, we detected transcriptomic changes in multiple tissues. The specific transcriptional responses observed suggest that bats limit viral replication and associated pathology by limiting the inflammatory response. This is largely achieved by tightly controlling expression and activation of acute phase proteins. Furthermore, we found evidence that important features of severe disease in humans, such as disseminated intravascular coagulation, are likely mitigated in bats through processes which involve vasodilation, iron metabolism, and avoidance of thrombosis through transcriptional changes in the coagulation pathway. Finally, we demonstrated transitioning of macrophages from the pro-inflammatory phenotype M1 to the anti-inflammatory, wound-healing phenotype M1.

Conclusions. Given the involvement of multiple pathways, we propose that Marburg and Ebola viruses induce a systemic response that results in an anti-inflammatory state that enables effective and lasting control of the infection. Our observations and analyses provide an experimental and computational framework for investigation of the resistance of bats to filovirus infection and identify genes involved in a systemic response of bats to Marburg and Ebola viruses that allows these animals to tolerate the infections. This framework and our results have the potential to aid in the development of new strategies to effectively mitigate and treat the effects of filovirus infections in humans.

KEYWORDS

BACKGROUND

The filoviruses Marburg (MARV) and Ebola (EBOV) cause severe and frequently fatal systemic diseases in humans [1]. The diseases caused by these viruses are characterized by hypotension, multisystem organ failure, sepsis-like symptoms, and disseminated intravascular coagulation (DIC) due to profound immune dysregulation accompanied by a cytokine storm [2]. The aggressive use of a recently approved EBOV vaccine has achieved control of the most recent large outbreak in the Democratic Republic of the Congo [3]. However, once the disease is manifested, medical intervention can prove to be insufficient, despite the recent progress in the development of antivirals and antibody-based treatments [4], [5]. Therefore, there is an ongoing need to better understand the pathobiology of these viruses. Remarkably, MARV and EBOV appear to cause no significant disease in their confirmed (MARV) or likely (EBOV) bat reservoirs, suggesting that understanding the molecular mechanisms of this resistance can be used to develop therapies for humans.

MARV has been isolated from the Egyptian rousette bat (ERB) (*Rousettus aegyptiacus)* [6]–[8], and ecological and experimental studies have demonstrated that this species serves as a reservoir for the virus [7], [9]. Experimental infections of ERBs with MARV have consistently demonstrated that despite viral replication in multiple tissues, animals develop a mostly subclinical disease. This is characterized by mild pathology, including transient elevation of alanine aminotransferase, elevated lymphocyte and monocyte counts, and some evidence of minimal inflammatory infiltration in the liver [10]–[14]. Transmission has been demonstrated between co-housed ERBs, and the virus is known to be shed in saliva, urine, and feces [9]. However, ERBs do not appear to develop a severe or chronic infection when exposed to MARV, and instead clear the virus and develop at least temporary immunity, including MARV-specific IgG [15].

Circumstantial evidence, including detection of EBOV RNA and anti-EBOV antibodies, suggests that multiple species of bats are also reservoirs for EBOV [16], [17]. However, infectious EBOV has never been isolated from a wild bat [18]. Although serological surveys have identified antibodies reactive to EBOV antigen in ERBs [19]–[21], experimental infection studies performed to date suggest that this bat species is refractory to infection [22], making it an unlikely candidate reservoir for the virus.

The ability of bats to tolerate viral infections has been a topic of considerable interest, and several models have been proposed to explain this phenomenon. Most of these are centered on the innate immune system, which includes the inflammatory response (induced by cytokines), phagocytosis, natural killer cells, and the complement system. One model posits that bats constitutively express interferons to maintain a basal level of innate immune activity [23], although the universality of this model in bats is uncertain [24], [25]. An alternative model suggests that the resistance of bats to clinical disease is due to a weakened innate immune response, which is attenuated by changes in some proteins such as the stimulator of interferon genes (STING/TMEM173) [26]. However, while this model may explain how viruses can survive in the animal, the means by which the infection is eliminated remains unclear. The similarity of innate immune responses to filoviruses in bat and human cell lines [27] despite distinct clinical outcomes of the infections in bats versus humans seems to contradict both theories and suggests that control of viral infections in bats is more complex.

We hypothesize that the response of bats to filoviruses is systemic, involving multiple interrelated processes, and that the difference in the responses to infection between bats in humans is due to evolutionarily divergent genes. To test this hypothesis, we have analyzed how MARV and EBOV affect global gene expression patterns in various bat tissues, with a particular focus on genes with evolutionarily divergent protein coding sequences. Our analysis of these transcriptomes begins to reveal a systemic organismal response that facilitates the ability of bats to survive filovirus infections and suggests potential therapeutic strategies for controlling human infection.

RESULTS

Inoculation of bats with MARV and EBOV results in detectable viral replication in some organs

Nine ERBs were either inoculated subcutaneously with 10^4 PFU of MARV or EBOV or were left uninfected (three in each group). Following inoculation, animals were observed at least daily and bled every other day. As

the goal of the study was to investigate changes in gene expression in the early phase of the disease, animals were euthanized 48 hours after becoming viremic. As expected, bats inoculated with MARV or EBOV showed no apparent clinical signs of disease or changes in behavior, with no significant effect on body weight and temperature (Fig. 1A, B). MARV or EBOV RNA was detected by droplet digital RT-PCR (ddRT-PCR) in the blood of infected bats, with MARV detected earlier and at a higher copy number than EBOV (Fig. 1C). MARV was detected by plaque assay in livers and spleens of all inoculated animals and in the salivary glands of two animals and kidneys of one animal (Fig. 1D). By contrast, EBOV was detected in the livers of two inoculated animals and could not be reliably detected elsewhere (Fig. 1E).

No pathology was observed in sections of female mammary tissue or in the testes of MARV-inoculated animals (Fig 1Fi,ii), that is consistent with previous reports [14]. However, Immunohistochemistry analysis demonstrated MARV antigen in both tissues, though this was focal in nature (Fig 1Fiii, iv), despite the absence of histopathological lesions in these organs. Two of the three EBOV-inoculated animals presented histopathological lesions in the liver, consisting of pigmented and unpigmented infiltrates of aggregated mononuclear cells compressing adjacent tissue structures, and eosinophilic nuclear and cytoplasmic inclusions (Fig 1Fv,vi), changes consistent with previous reports [20], [22]. Immunohistochemical analysis demonstrated EBOV antigen in the liver of one animal, but very few foci were found (Fig 1Fvii, viii), suggesting limited viral replication.

MARV and EBOV infection affects the transcriptome of multiple organs

To examine the transcriptional response to filovirus infections, we performed deep sequencing of mRNA from liver, lungs, spleen, kidney and large intestine collected from filovirus inoculated and uninfected bats (Methods, Table ST1). Consistent with prior reports that liver is the primary target of MARV [28], and with our findings (Fig. 1), MARV transcripts were the most abundant in liver (79 transcripts-per-million or tpm) and also present in spleen (56 tpm), intestine (10 tpm) and lungs (2 tpm) but not present in kidneys (Table ST2). EBOV transcripts were detected at very low levels (< 1 tpm) in the livers of inoculated bats and were not detectable in other tissues.

Remarkably, although the highest levels of viral transcripts were detected in the liver, gene expression patterns were altered in all three tissues subjected to transcriptome analysis, liver, spleen and kidneys, involving thousands of genes, suggesting a systemic response (Fig. 2, 3, S1). The changes were higher in the livers of bats infected with MARV than EBOV (Fig. 2), which can be explained by the much more abundant replication of MARV (Fig. 1). The sets of genes affected by the two infections were not completely identical, suggesting some responses are virus-specific (Fig. 3, S1). The differences in the patterns of gene expression could also arise from different levels of MARV and EBOV replication.

Analyzing evolutionarily divergent bat genes as an approach for understanding the response to filovirus infection

To identify molecular mechanisms underlying the difference in clinical response between bats and humans, we reasoned that the genes responsible for the resistance in bats would be more divergent in their protein coding sequences from their homologues in humans than genes whose products function similarly in both species. Focusing first on divergent genes would also simplify the computational analysis of the transcriptomes, helping to identify relevant pathways.

Another benefit of limiting the genes to the divergent set is that we ameliorate the multiple-testing problem, as we show in the table of 194 genes that we focus on in this study (available on the companion website http://katahdin.girihlet.com/shiny/bat/), 130 genes have false discovery rate (FDR) values below 0.25. If we had started with the full list of genes and used the FDR values calculated for that set, only 90 of the genes relevant to the pathways here would have remained (with FDR < 0.25), since the larger set of background genes would have increased the number of possible false positives that could occur just by chance.

Using this strategy, we first identified a set of 2,439 bat genes that were diverged from their human or mouse homologues according to our criteria (Fig. 4, Methods). From this set, only a subset of 264 genes were expressed at more than 20 tpm in at least one set of liver samples (MARV, EBOV, or uninfected). Of these 264

4

genes, the expression of 151 genes was different in the livers of either MARV or EBOV infected bats relative to uninfected animals (Fig. S2). These 151 genes were used for the first step of pathway analysis (Tables ST3-8).

The most abundant group in this set comprised genes related to mitochondria (20 genes), followed by genes involved in the vascular system (19), innate immunity (16), tissue regeneration and apoptosis (15), macrophages (13), inflammation (10), metabolism and fatty-acid oxidation (8), T cells (4), complement system (2), digestion (5), and toxin processing (3).

Using the distribution of divergent genes as a guide and available knowledge about the pathways in humans that involve these functions, we then focused on the *entire* transcriptomes of the following systems: 1) innate immune system (Fig. S3) which includes the interferon stimulated genes (Fig. S4), most of which are conserved between bats and humans, the inflammatory response, phagocytosis by macrophages, natural killer cells, and the complement system; 2) inflammatory response, including acute phase proteins, macrophages activities involving metabolism, fatty-acid oxidation, mitochondrial abundance and function, and tissue regeneration and apoptosis; and 3) blood-related physiological systems, involving the regulation of blood pressure, coagulation, and iron homeostasis.

Effects of filovirus infections on the transcriptional response

MARV and EBOV infection induce initial inflammation, evidenced primarily by an acute phase response. Acute phase proteins (APP) are produced by hepatocytes in the liver in response to inflammatory cytokines, such as interleukin (IL)-1, (IL-6) and tumor necrosis factor α (TNFα) and are an important part of the innate immune response [29]–[31]. Upon inflammation, the concentration of positive APPs, including serum amyloid A1 (SAA1) and serum amyloid A2 (SAA2), increase dramatically (> 10-fold) in the serum [32], while the concentration of negative APPs, including transferrin (TF) and albumin (ALB), decreases [33].

We found that MARV, and to a lesser extent EBOV, infection induced an APP response in liver, spleen and kidney, with the largest changes in APP expression (>10-fold) observed in the liver (Table 1, Fig. 5, S2A, S2B). SAA1 and SAA2 expression increased to a similar degree in all tissues, including tissues in which the viruses were not detected. At the same time, we detected no expression of C-reactive protein (CRP), an APP used as a marker for inflammation/acute-phase-response in humans (Table 1, Fig. 5), likely because it is not expressed in bats. We draw this conclusion in part because we were also unable to identify evidence of a CRP response in an analysis of public mRNA-seq data from infected samples from various species of bats (data not shown). Consistent with the induction of SAA1 and SAA2, we also detected induction of other markers of inflammation including orosomucoid 2 (ORM2), ceruloplasmin (CP), hepcidin (HAMP) and the microsomal glutathione S-transferases (MGST1, MGST2) [34] (Table 1, Fig. 5).

Expression of key components of the classical complement pathway is inhibited by filovirus infection. The complement system, a part of the immune system, has three pathways: the classical pathway, the mannose-binding lectin pathway and the alternative pathway [35]. The classical pathway recognizes antibodies bound to antigens, the lectin pathway is triggered by the binding of lectin to sugar molecules on pathogens, and the alternative pathway is triggered by C3 recognition of a hydroxyl or amino group of a molecule on a pathogen surface.

Several key genes associated with the complement pathway were upregulated by filovirus infection, including complement component 3 precursor pseudogene (C3P1), complement C4B (C4B), complement C5 (C5), complement C9 (C9), complement C6 (C6), and mannan binding lectin serine peptidase 1 (MASP1), while others were downregulated or not expressed, including complement C1r (C1R), complement C3 (C3), complement C8 gamma chain (C8G), and mannan binding lectin serine peptidase 2 (MASP2) (Fig. 5, S5A). These observations indicated that the complement pathway is affected by filovirus infection and suggests that some protective mechanisms involving the complement system such as antibody-dependent complement deposition may be compromised.

Infected bats exhibit transcriptional signatures of T cell activity. CD4$^+$ T cells recognize peptides presented on MHC class II molecules expressed by antigen presenting cells (APCs), while CD8$^+$ T cells recognize peptides presented by MHC class I molecules, expressed by all nucleated cells [36]. CD8$^+$ T cells are cytotoxic and can

kill virus-infected cells. Multiple genes expressed only by CD8[+] T cells, including C-C motif chemokine ligand 3 (CCL3), annexin A1 (ANAX1), T cell immunoglobulin and mucin domain containing 4 (TIMD4) and magnesium transporter 1 (MAGT1), were upregulated in the liver by filovirus infection (Fig. 5, S5B), indicating at induction of T cell response.

EBOV and MARV infections affect blood related physiological systems. Blood carries nutrients, oxygen, as well as the cells and molecules that constitute the immune response and inflammation. The key physiological systems connected to the immune response and inflammation are iron homeostasis, blood pressure, and blood coagulation. We found that expression of genes involved in regulation of all three of these systems was affected by MARV and EBOV infections, as detailed below.

Genes regulating iron homeostasis. The absorption and availability of iron, an essential component of heme needed for oxygen transport, is tightly regulated [37]. In humans, most iron in the body is located in hemoglobin (66%) and myoglobin (10%) [38], while the remainder is stored mostly in macrophages in the liver, which take up iron through the CD163 receptor. Iron is exported from macrophages and absorbed from food [39] through ferroportin (SLC40A1/FPN1).

MARV and EBOV infections changed the expression of multiple genes involved in iron homeostasis. Hepcidin (HAMP), which controls iron homeostasis by binding ferroportin [40], [41] thereby causing its degradation as well as blocking the export of iron, was induced in infected livers (Fig. 5, S6, Table 1). Similarly, ceruloplasmin (CP) (an APP, Table 1), which enables the formation of the transferrin-iron complex and is also involved in processing copper [42], was also induced. In the cytosol, iron is bound to ferritin (comprised of a heavy chain, FTH1 and a light chain FTL), synthesized by cells in response to increased iron [41]. In mitochondria, iron is bound to the mitochondrial ferritin (FTMT) [43]. Both FTH1 and FTMT were downregulated in MARV-infected but not EBOV-infected bats (Fig. 5, S6); the difference can be explained by higher MARV replication relative to EBOV. Furthermore, MARV infection was associated with lowered hemoglobin (HBB) expression, suggesting impairment of red blood cell production. Consistent with this conclusion, CD164, which suppresses hematopoietic cell proliferation, was also upregulated by MARV, and to a lesser degree, EBOV infection (Fig. 5, S6). Thus, hematopoiesis may be impaired in MARV-infected ERBs, but not in EBOV-infected ERBs, the difference consistent with the levels of viral replication for the respective viruses in ERBs. Furthermore, as the higher levels of HAMP in EBOV-infected bats do not result in lower levels of FTH1/FTMT, the regulation of iron by HAMP in bats is likely to be diverged from the homologous process in humans [40], [41].

Genes regulating blood pressure. The primary means of blood pressure regulation is renal expression of renin, which converts angiotensinogen (AGT) to angiotensin I. Angiotensin converting enzyme (ACE) converts angiotensin I to angiotensin II, which constricts blood vessels to increase blood pressure. Both MARV and EBOV infections downregulated AGT, resulting in depletion of the substrate for ACE, limiting the potential for blood pressure to increase even with upregulation of ACE (Fig. 5, S7). Another mechanism regulating blood pressure involves cytochrome P450 family 11 subfamily B member 2 (CYP11B2), which increases aldosterone levels that increases blood volume and consequently, the blood pressure. CYP11B2 was found to be down regulated in MARV infected bats in a previously published study [44] and in this study (Fig. 5), further suggesting the possibility that low blood pressure is a response to MARV infection. In the case of EBOV, CYP11B2 was not downregulated (Fig. 5), possibly due to the low level of viral replication. However, blood pressure was not measured in the bats in this study.

Genes regulating in blood coagulation. Mechanisms that control blood pressure also impact coagulation and vice versa, increasing coagulation leads to higher blood pressure through constriction of blood vessels. For example, fibrinogen B (FGB) is cleaved by thrombin to generate fibrin (which forms the clots), and cleavage products of FGB promote vasoconstriction.

Coagulation or clotting is a complex process involving a cascade of activation reactions that finally results in thrombin forming clots (Fig. S8). Since many of the gene products involved need to be activated, information on the coagulation state is not readily observed from mRNA abundance, which can at most indicate the protein abundance, not their states of activation. Of the genes in the coagulation pathway, MARV and EBOV infections upregulated one set of genes: coagulation factor IX (F9), tissue factor pathway inhibitor 2 (TFPI2), serpin

6

family E member 1 (SERPINE1), SERPIND1, fibrinogen beta chain (FGB), plasminogen activator tissue type (PLAT), and downregulated another set: thrombin (F2), vitronectin (VTN), SERPINF1, SERPINC1, coagulation factor X (F10) and plasminogen (PLG) (Fig. 5, S8, S9). There were other genes which were not strongly up or down regulated upon the infections.

In the coagulation cascade (Fig. S8), tissue factor III (encoded by the F3 gene) activates coagulation factor VII (encoded by the F7 gene), which then activates several factors in the cascade, eventually activating coagulation factor X (encoded by the F10 gene) which in turn activates coagulation factor II (encoded by the F2 gene) to form thrombin, which enables fibrin synthesis, leading to clot formation. Thrombin is also involved in a positive feedback enabling more thrombin to be created. An opposing process involves the conversion of plasminogen to plasmin (facilitated by the plasminogen activators uPA and tPA) which promotes fibrinolysis [45], leading to dissolution of clots. SERPINE1 inhibits this process by inhibiting the activity of uPA and tPA.

F3 was not abundant in any sample, and F2 was downregulated in response to MARV and EBOV infections, suggesting thrombin production was curtailed; SERPINE1 was upregulated, which can only prevent dissolution of clots, but does not enhance coagulation directly. Angiotensin II, which increases blood pressure, also increases thrombin formation and impairs fibrinolysis [46]. AGT, the precursor of angiotensin II, was downregulated by MARV and EBOV infections, which is expected to lower angiotensin II levels and concomitantly decrease blood pressure and coagulation. Thus, we conclude that filovirus infections of bats lead to reduced coagulation. Together, these events are likely to reduce the effects of inflammation on the vascular system.

MARV and EBOV infection leads to an early transition from proinflammatory M1 to anti-inflammatory M2-dominated populations of macrophages. Macrophages recognize and phagocytize microbes and damaged host cells, as a part of the innate immune response, and are an important early target for filoviruses [28]. Macrophages can either be in the M1 state, an inflammatory state enabling apoptosis, or in the M2 state, anti-inflammatory state assisting tissue regeneration (Fig. S5C). A key difference between the M1 and M2 states lies in their metabolism; the M1 state is characterized by hypoxia and glycolysis metabolism [47], while the M2 state is characterized by fatty acid metabolism and elevated mitochondrial activity [48].

We have found that key markers of the M1 state were upregulated in livers of infected bats and more so in MARV infected animals. These markers included interferon regulatory factor 5 (IRF5), nuclear factor kappa B subunit 1 (NFKB1), adaptor related protein complex 1 subunit gamma 1 (AP1G1), signal transducer and activator of transcription 1 (STAT1), and suppressor of cytokine signaling 3 (SOCS3) (Fig. 5, S10, S11). Likewise, hypoxia inducible factor 1 subunit alpha (HIF1A) [49]–[51], which promotes mitophagy and glycolysis metabolism to induce M1 polarization, was also upregulated in infected livers, again more so in MARV infection. Pyruvate kinase M1/2 (PKM1/2), which activate HIF1A, and pyruvate dehydrogenase kinase 1 (PDK), which enhances M2 polarization in response to hypoxia [52], were also upregulated. Again, upregulation occurred to a greater degree in MARV than EBOV (Fig. 5, S10, S11).

The M2 state markers mannose receptor C-Type 1 (MRC1), arginase 1(ARG1), IL-10 and transforming growth factor beta 1 (TGFB1) [53] , were highly expressed in livers of bats infected with both viruses (Fig. 5, S10, S11F), suggesting that M2 macrophages were also present. Several genes related to fatty acid oxidation in M2 macrophages were upregulated by MARV and EBOV infections (Tables ST3A, ST5, ST7). Particularly, we observed upregulation of carnitine palmitoyl transferase 2 (CPT2), a gene associated with fatty acid transport; the effect was greater in MARV infection. Infected bats also exhibited upregulation of multiple markers of mitochondria abundance, another characteristic of M2 macrophages (Fig. S11C). These included transcription factor A mitochondrial (TFAM), OPA1 mitochondrial dynamin like GTPase (OPA1), mitofusin (MFN1/2), and dynamin 1 like (DNM1L). Also upregulated upon MARV infection are genes involved in mitochondrial biogenesis [54], hepatocyte growth factor/tyrosine kinase MET (HGF/MET) and peroxisome proliferator-activated receptor gamma coactivator 1 alpha (PPARGC1A).

Prolonged M1 activity can be harmful to tissues due to their induction of inflammation and apoptosis. This activity is modulated by a negative feedback system that shifts macrophages from the M1 state to the M2 state

7

[55], [56], controlling inflammation during infection and facilitating the transition to tissue repair and regeneration [57], [58]. In our data, the transcriptomes of the MARV-infected liver samples suggest a more equal representation of M1 and M2 macrophages, while in the EBOV-infected liver samples, M2 macrophages dominated. These data suggest that the presence of both M1 and M2 macrophages in case of MARV infection might be indicative of the greater magnitude and duration of its replication, and the presence of M2 macrophages in case of EBOV infection indicates at a conversion from M1 to M2 state after the virus is cleared.

Consistent with this conversion, we observed changes in cellular energy metabolism that are associated with the M1 to M2 transition. The mitochondrial glycerol-3-phosphate dehydrogenase (GPD2), identified as a contributor to the shift in core macrophage metabolism associated with the M1 to M2 transition during infection [59], was found to be upregulated by filovirus infections (Fig. 5, S11B). Filovirus infections of bats resulted in upregulation of hypoxia inducible factor 1 subunit alpha inhibitor (HIF1AN), the inhibitor of HIF1A; inactivating HIF1A also promotes M2 polarization [60], suggesting a mechanism of M2 polarization in filovirus infected bats. Interestingly, in MARV-infected bats, which demonstrated a mixed M1-M2 response, we observed downregulation of ferritin (FTH1/FTL), which is synthesized in response to iron, and HBB (a reflection of hemoglobin levels), and upregulation of HAMP, which reduces the levels of iron. In EBOV-infected animals, which demonstrated a more pronounced M2 response (Fig. S11D, S11E), no downregulation of FTH1/FTL, a small upregulation of HBB and a stronger upregulation of HAMP was detected. These data are consistent with the data that an increased availability of iron promotes the M1 to M2 polarization shift [61]. These lines of evidence further support our findings of a polarization bias toward M2 during filovirus infections.

DISCUSSION

Over the past few years, multiple high-impact pathogens associated with bats have emerged or re-emerged, the most notable of which are MARV, EBOV, SARS-CoV and SARS-CoV-2. As a result, the role of bats as reservoirs for a diverse array of viruses and their ability to tolerate viral infections that cause severe disease in humans has become a topic of considerable interest. A number of hypotheses have been proposed to explain this unique aspect of bat biology. Most of them are centered on the innate immune system. In these hypotheses, various aspects of bat innate immunity are either more or less potent than their human counterparts. One of these hypotheses posits that some bat species constitutively express interferons, leading to a basal level of innate immune activation [23]–[25]. However, in humans persistent interferon expression leads to lowered resistance to infections due to dysregulation of iron homeostasis [62] and are associated with various pathologies [63]. Patients with trisomy have elevated constitutive expression of interferons and exhibit weaker immune response in COVID-19 [64], [65]. These pathologies and prior work with filoviruses demonstrating that the innate response in bat cells is robust, and similar to that observed in human cell lines [27] suggests that interferons in bats are induced similarly to that humans. Thus, the hypothesis of constitutive high expression of interferons in bats is inconsistent with our data. Another hypothesis suggests that components of the innate immune response, e.g., stimulator of interferon response cGAMP interactor 1 (STING/TMEM173), are less effective in bats, allowing viruses to survive in the host [26]. Although this mechanism might explain the ability of bats to tolerate infections with a diverse range of viruses without a severe inflammation and disease, it cannot explain the ability of bats to effectively clear filoviral infections. The clearance of filoviral infections by bats suggests a more complex process involving the innate and likely adaptive immune systems.

In this study, all MARV-inoculated bats were productively infected, and our virology and histopathology data in MARV-infected bats are consistent with previous reports, including viral replication in the mammary glands and testes [14]. Unexpectedly, evidence of productive, while limited, infection was identified in two of the three EBOV inoculated animals, although the detection of virus in the livers by plaque assay and immunohistochemistry identified only a small number of foci in the liver of one animal. These data contrast the prior reports [66] and suggests that ERBs may not be truly refractory to EBOV infection. However, given the low titers detected, and the limited nature of the observed immunostaining, it remains to be determined whether the virus can be maintained in this particular bat species in nature.

To reveal molecular mechanisms that underlie the resistance of bats to MARV and EBOV, we developed a model of bat response to filovirus infections (Fig. 6). Our analysis shows that the majority of interferon response genes are not divergent from their human homologs, consistent with our prior observations that the innate responses to filoviruses are quite similar in human and bat cells [27]. These structural and functional similarities suggest that the ability of bats to tolerate infections with multiple viral pathogens without a disease is unlikely to be explained by features of the interferon response.

A key feature of filovirus infection in humans is an inflammatory response leading to the expression of APPs and stimulation of M1 macrophages. In humans, a major APP protein is CRP, which binds to microorganisms, including viruses, assists in complement binding to foreign and damaged cells, and enhances phagocytosis by macrophages (opsonin-mediated phagocytosis) [67]. We found no evidence of CRP expression in bats by mRNA-seq data, while other APPs were conserved and are listed in Table 1. It is possible the lack of CRP response is responsible for a lowered inflammation, explaining the resilience of bats to infections by many viruses. As a counterargument, we must keep in mind that in mice, CRP is not an acute phase protein [68].

We found evidence in the response of complement genes that an effector component of the antibody response may be weakened by incomplete complement activation. This is consistent with the previous reports that antibody-mediated virus neutralization is not the dominant mechanism of filovirus clearance in ERBs [69]. The robust CD8$^+$ T cell activity implied by our mRNA-seq data suggests that control and clearance of filovirus infection in bats may instead depend upon a robust T cell response. This is consistent with what is known in humans, where individuals who recover from filovirus infections tend to mount robust T cell responses [70]–[72], and have higher levels of CD40L expression, a marker for T cell activity [72], although recovery of humans from filovirus infections also correlates with induction of the antibody response [73].

The macrophage response was one of the more notable points of divergence between the human response to filovirus infection and what we observed in infected bats. We identified markers of both M1 and M2 macrophages in ERBs infected with MARV, suggesting that macrophage populations in the animals were in the process of switching from the classically pro-inflammatory M1 polarization to the M2 state, which is conventionally associated with anti-inflammatory processes, tissue repair, and regeneration. In particular, the modulation of the innate response facilitated by M2 macrophages is important for T cell mediated clearance of viruses [55]. In EBOV-infected animals, where viral replication was far more limited, our data indicate that the macrophage population was further along in the transition to M2 polarization by the time of euthanasia, likely due to the viral replication being successfully controlled. The generalized anti-inflammatory state observed in bats during filovirus infection, especially the early switch to M2 macrophage polarization, may suggest a way to prevent the immunopathology associated with filovirus infections in humans, including cytokine storm and DIC. Supporting this, an mRNA-seq study conducted with PBMCs isolated from EBOV-infected humans found that individuals who succumbed to disease showed stronger upregulation of interferon signaling and acute phase response-related genes than survivors during the acute phase of infection [74], suggesting that a moderated innate response improves outcomes in filovirus infection. Furthermore, pharmacological inhibition of toll-like receptor 4 signaling promotes survival in an animal model of filovirus infections [75].

Our data suggest that the bat vascular response to infection differs from that in humans. Humans infected with MARV or EBOV frequently present with hemorrhagic manifestations and dysregulated coagulation in the form of DIC [18]. We identified transcriptional patterns consistent with vasodilation and reduced potential for coagulation. This could result in a state in which blood pressure is lower than normal, and coagulation is reduced. This state may be protective, as it might be expected to prevent DIC. These findings are consistent with results from a study in humans infected with EBOV which analyzed 55 biomarkers in blood and found that viremia was associated with elevated levels of tissue factor and tissue plasminogen activator, consistent with coagulopathy [76].

Our results suggest that reducing the hyperinflammatory response [75] or controlling coagulopathy [77] in humans during filovirus infection may have a therapeutic benefit by preventing damage to the host and allowing other processes to clear the infection. This could be achieved by inhibiting IL-6 signaling either by targeting the cytokine (by Clazakizumab, Olokizumab, Sirukumab or Siltuximab), or its cognate receptor (by

Tocilizumab or Sarilumab) or its trans-signaling by blocking the soluble receptor (sIL-6R) (by Olamkicept) [78]. Strikingly, a recent COVID-19 study demonstrated tocilizumab reduced the likelihood of progression to the composite outcome of mechanical ventilation or death [79].

We demonstrated that in bats, filovirus infections upregulates MGST1 and MGST2 (Table 1), which induce leukotrienes (LTC4) and prostaglandin E, both of which induce inflammation [34]. This is a potential druggable target, as these molecules are targeted by several therapeutic agents. Thus, inflammation caused by filovirus infections could also be potentially targeted by another class of anti-inflammatory agents such as LTC4 inhibitors, used to treat asthma.

Our results also suggest that upon filovirus infections bats may naturally vasodilate and reduce their blood pressure (mimicking the action of ACE inhibitors), while the endothelial system becomes anti-thrombotic. This suggestion is consistent with the results of the field trials of ACE inhibitors and statins in human Ebola virus disease that have already demonstrated some success [80]. The potential involvement of vasodilation also suggests that prostaglandin I_2 (PGI$_2$, known as the drug Epoprostenol), a powerful vasodilator and anti-coagulant that acts by binding to the prostacyclin receptor [81], could be investigated in human filovirus infections as a means of emulating the physiological conditions (low blood pressure and coagulation) that our data suggest may have protective effects.

In humans, high levels of HAMP cause iron to be sequestered in the liver, reducing levels of iron in blood (lower ferritin). Our observations indicate that in EBOV infected bats high HAMP expression is decoupled from the levels of iron, as both ferritin and HAMP are induced. Thus, HAMP inhibitors, which are used to treat anemia, might recreate in humans the state seen in bats under filoviral infection.

CONCLUSIONS

The changes in gene expression patterns that we have observed in infected bats suggest that the pathways regulating coagulation, vasodilation, iron homeostasis, inflammation, the interferon response and the adaptive response contribute to the unique response of bats to filovirus infection. The aim of this systemic response appears to be avoiding immunopathology by tempering of the overall response to infection. In particular, the anti-inflammatory state (the M1 to M2 transition of macrophages) and the altered state of the blood-related physiological systems appear to be important to preventing pathology and facilitating the ultimate clearance of the virus.

Our observations and analyses provide an experimental and computational framework for investigation of the resistance of bats to filovirus infection and identify genes involved in a systemic response of bats to MARV and EBOV that allows these animals to tolerate the infections. This framework and our results have the potential to aid in the development of new strategies to effectively mitigate and treat the effects of filovirus infections in humans.

METHODS

Viruses. Recombinant wild-type MARV, strain 371Bat, was recovered similarly in BHK-21 cells [82] and passaged twice in Vero E6 cells for amplification. Recombinant wild-type EBOV, strain Mayinga, was recovered from the full-length clone and support plasmids in HEK 293T [83] cells and passaged twice in Vero E6 cells for amplification.

Bat experimental protocol. All animal procedures were performed in compliance with protocols approved by the Institutional Animal Care and Use Committee at the University of Texas Medical Branch at Galveston.

Adult ERBs were obtained from a commercial source and quarantined for 30 days under ABSL-2 conditions. Animals were implanted with microchip transponders for animal ID and temperature data collection. For studies with MARV and EBOV, animals were transferred to the Galveston National Laboratory ABSL-4 facility. Animals were segregated into groups of three. In the infection study, except for one MARV-infected male, all bats were female. Male bats are prone to fighting, and as such, should not be cohoused in non-flight caging. Each group was housed in a separate cage for inoculation with the same virus. After acclimation to the facility, animals

were anesthetized with isoflurane and infected subcutaneously in the scapular region with 10^4 PFU (titrated on Vero E6 cells) of MARV or EBOV. Every other day, animals were anesthetized by isoflurane, weighed, temperature was determined via transponder, and 100-150 µL of blood was collected from the propatagial vein. Blood was inactivated in 1 mL of TRIzol reagent (Thermo-Fisher Scientific). Samples were then removed from ABSL-4 containment, and RNA was extracted. ddRT-PCR with primers specific to the nucleoprotein (NP) gene was used to detect viremia. Animals were euthanized 48 hours after detection of MARV or EBOV RNA load under deep isoflurane sedation via cardiac exsanguination confirmed by bilateral open chest. Tissues were collected (listed in Table ST1) and immediately homogenized in an appropriate volume of TRIzol reagent and stored at -80°C. 1 cubic centimeter (cc) tissue sections were homogenized in minimal essential media (MEM) supplemented with 10% fetal bovine serum and stored at -80°C. Additional tissue sections were fixed in 10% neutral buffered formalin for histopathology. Tissues and PBMCs were also collected from three uninfected control animals.

Leukocyte isolation. Leukocytes were isolated using ACK lysis buffer (Gibco). Ten volumes of lysis buffer were added to whole blood, incubated for 2-3 min, and then neutralized with complete DMEM medium containing 10% FBS. Following neutralization, samples were centrifuged at 250 g for 5 min at 4°C, after which the supernatant was decanted from the pellet. This process was repeated several times per sample until a white pellet of cells free of contaminating red blood cells remained. Because density gradient purification was not performed on these samples prior to or after red blood cell lysis, these leukocyte preparations were assumed to contain granulocytes in addition to PBMCs.

mRNA sequencing. Total RNA was isolated from bat tissues using Ambion's RNA isolation and purification kit. For most samples, polyA-tailed mRNA was selected using beads with oligo-deoxythymidine and then fragmented. A few samples with poor RIN (RNA Integrity Number) scores were treated with Ribominus (targeting human ribosomal RNA) to enrich for polyA-tailed mRNA before fragmentation. cDNA was synthesized using random hexamers and ligated with bar-coded adaptors compatible with Illumina's NextSeq 500 sequencer. A total of 88 samples were sequenced on the NextSeq 500, as 75 base pair single reads.

Bat mRNA sequence database. The extant bat genomes are not complete, and a comprehensive mRNA database does not exist. Thus, for this study, we constructed a custom non-redundant reference bat mRNA sequence database, which is available at https://katahdin.girihlet.com/shiny/bat/. We started with existing genome annotations [84]. The complications arising from splice variants were avoided by keeping only the longest transcript for each gene. We added missing annotations/sequences (e.g., CYP11B2 and PLG) to our database by assembling reads from our own sequence data. These required custom scripts as there often was not enough reads covering a transcript, which precluded the use of standard assembly tools. The gene sequences were collected from different bat species, so error-free reads might not map perfectly to the transcripts in the database. The database has sequences of 18,443 bat mRNAs and includes MARV and EBOV sequences. The gene sequences were collected from different bat species.

The genes were identified by homology to mouse and human genes, 16,004 bat genes had high similarity to human or mouse homologues, as defined by BLASTn with default settings identifying matches spanning the length of the mRNA. The set of remaining genes (2439) were labelled as divergent. Of these, 1,548 transcripts could be identified by increasing the sensitivity of BLASTn by reducing the word-size from 11 to 9, which is equivalent to matching at the protein level. Of the remaining 891 putative transcripts, homologues for 182 could be identified on the basis of partial homology and domain structure, while the remainder (709 sequences whose names start with UNDEF) belonged to one of four classes, 1) aligned to un-annotated transcripts in the human genome, 2) non-coding RNAs, 3) transcripts unique to bats, or 4) assembly errors. We use capitalizations to represent bat gene symbols, as in the human gene nomenclature.

To identify genes within these divergent set that are relevant to our study, we then selected a subset of genes that had good expression (defined as tpm > 20) in at least one class of liver samples (MARV-infected, EBOV-infected or uninfected) and responsive in either MARV-infected or EBOV-infected bat livers, which we defined as upregulated ($\log_2$ ratio > 0.6), or downregulated ($\log_2$ ratio < -0.6). We were left with 151 genes that are the foundation of our analyses of pathways involved in the response to filoviruses (Tables ST3-8).

11

Expression Analyses. To determine transcript expression levels, we used Kallisto [85], because this tool uses pseudo-alignments and is relatively more tolerant of errors/variants in reads, which we expect here because the reads and mRNA sequences in the database do not always come from the same species. Kallisto uses a parameter "k" while indexing the database to specify how sensitive it is to matches with smaller k values leading to more spurious hits. We empirically determined k=23 to be an appropriate parameter value with which to index the reference mRNA dataset. We used tpm value as the transcript expression levels to determine changes in expression across samples.

We used viral transcripts to identify infected samples, which has previously helped us to identify and correct errors in annotation in some of the cell line data and also identified a problem with a published dataset [86], where all the naïve (uninfected) samples showed signs of viral infection. Furthermore, to ensure there was no mislabeling of tissue samples from different bats, we used single nucleotide variants in the sequenced reads to confirm that all tissue samples from an individual had the same set of variants.

Using clustering based on expression profiles and considering individual interferon responsive genes, it was clear that one non-infected control bat liver sample (labeled *cb1* in the shiny tool) was reacting to some stimulus (injury or infection) compared to the other two control samples (*cb2* and *cb3* in the shiny tool). Correlations between samples based on gene expressions profiles (Table ST9) shows that cb1 is an outlier and is closer in profile to the MARV-infected samples, suggesting an inflammatory response is present. This animal had an injury, and it is likely that inflammatory processes associated with this were responsible. Since we are interested in the innate response to infections, we had to exclude *cb1* from the controls and all analyses, but *cb1* data are available for exploration in the *filobat* tool. Most of our analyses concentrated on liver RNA transcripts since it had the strongest response, and the genes indicated that a variety of cell types were involved in the response, capturing the systemic nature of the response. Liver function impacts a wide range of systems involving inflammation, iron homeostasis, and blood pressure. Other organs, such as kidney and spleen provide additional support for what is observed in the liver. For some genes, we also used the transcriptional response in kidney (renin) and/or spleen (STING) in order to understand the regulation of pathways (e.g., renin is expressed in kidney and regulates the blood pressure system).

Tools for data exploration and interrogation. To allow exploration of the data across various samples on a gene-by-gene basis, as well as analysis of viral expression in the samples, we developed a browser-based tool, *filobat*, using *Shiny* in R (http://katahdin.girihlet.com/shiny/bat/). Samples can also be compared using scatter plots and hierarchical clustering.

Statistics. Large changes in expression profiles were readily detected by comparing averages across replicates, since such changes are less affected by noise; however, subtle changes (less than 2-fold) were difficult to reliably detect due to lack of power in the sample size and variability between samples and are mostly not considered. Since only two samples were left in the controls, we could not use the t-test to compute p-values for comparisons between the EBOV and control samples. Correlations between the various samples (Table ST9) suggest that we could perform comparisons between the MARV and the EBOV (which are broadly similar to the uninfected samples), and over 130 of the 194 genes highlighted in the study have FDR values below 0.25. Many of these (40 genes) would have exceeded this threshold if all the genes in the study were considered. The full table of genes with the p-values and FDR is available on the companion website (http://katahdin.girihlet.com/shiny/bat/).

Pathway analyses. A fundamental assumption underlying our study is that bats are mammals that possess innate and adaptive responses to infections that roughly mirror those seen in humans. The data from comparative filovirus infections in human and bat cell lines supports this assumption [27]. To identify pathways of interest from particular genes, we used GO/pathways annotations of the human counterparts [87] and grouped them into functions that provided themes in the dataset. Using these themes, we identified other differentially expressed genes sharing these themes, identified by the GO annotations for human and mouse genes. This allowed us to build a picture of the pathways triggered by filovirus infections and delineate the ways in which the systemic bat responses differs from those seen in humans.

12

DECLARATIONS

Ethics approval and consent to participate. Not applicable.

Consent for publication. Not applicable.

Availability of data and materials. All data underlying the balloon plots is available as csv files on the filobat website (http://katahdin.girihlet.com/shiny/bat/). Additionally, a fasta-format file, containing all the mRNA sequences used in our analysis, is also available on the website. The raw sequencing reads will be deposited with GEO, and the filobat site has several tools for analysis and exploration of data.

Competing interests. No competing interests declared.

Authors' contributions

CFB, AB and RS conceived the project, and all authors designed the experiments

AJR and ANP performed the bat study under BSL-4 containment.

KAF performed histological analysis.

MFC helped analyze the mRNAseq data

TMS, KRS, and SH worked on isolation, purification of RNA

KRS, SH and ADJ performed mRNAseq

ADJ developed the systems analyses and helped develop the filobat tool

RS developed all software for analyses and the filobat tool

CFB supervised work with RNA

TWG supervised histological studies

AB supervised work with bats

AB, ADJ, AJR, ANP and RS wrote the manuscript

All authors discussed and agreed on the results and approved the manuscript.

REFERENCES

[1] V. Rougeron, H. Feldmann, G. Grard, S. Becker, and E. M. Leroy, "Ebola and Marburg haemorrhagic fever," *J. Clin. Virol.*, vol. 64, pp. 111–119, Mar. 2015, doi: 10.1016/j.jcv.2015.01.014.

[2] T. W. Geisbert *et al.*, "Pathogenesis of Ebola Hemorrhagic Fever in Primate Models," *Am J Pathol*, vol. 163, no. 6, pp. 2371–2382, Dec. 2003.

[3] J. Zarocostas, "Hope for the Ebola outbreak in DR Congo," *Lancet*, vol. 395, no. 10226, p. 773, Mar. 2020, doi: 10.1016/S0140-6736(20)30495-5.

[4] K. Dhama *et al.*, "Advances in Designing and Developing Vaccines, Drugs, and Therapies to Counter Ebola Virus," *Front Immunol*, vol. 9, p. 1803, 2018, doi: 10.3389/fimmu.2018.01803.

[5] M. G. Kortepeter, K. Dierberg, E. S. Shenoy, T. J. Cieslak, and Medical Countermeasures Working Group of the National Ebola Training and Education Center's (NETEC) Special Pathogens Research Network (SPRN), "Marburg virus disease: A summary for clinicians," *Int J Infect Dis*, vol. 99, pp. 233–242, Oct. 2020, doi: 10.1016/j.ijid.2020.07.042.

[6] J. S. Towner *et al.*, "Isolation of genetically diverse Marburg viruses from Egyptian fruit bats," *PLoS Pathog*, vol. 5, no. 7, p. e1000536, Jul. 2009, doi: 10.1371/journal.ppat.1000536.

[7] B. R. Amman *et al.*, "Seasonal Pulses of Marburg Virus Circulation in Juvenile Rousettus aegyptiacus Bats Coincide with Periods of Increased Risk of Human Infection," *PLOS Pathogens*, vol. 8, no. 10, p. e1002877, Oct. 2012, doi: 10.1371/journal.ppat.1002877.

[8] B. R. Amman *et al.*, "Isolation of Angola-like Marburg virus from Egyptian rousette bats from West Africa," *Nat Commun*, vol. 11, no. 1, p. 510, Jan. 2020, doi: 10.1038/s41467-020-14327-8.

[9] A. J. Schuh *et al.*, "Modelling filovirus maintenance in nature by experimental transmission of Marburg virus between Egyptian rousette bats," *Nat Commun*, vol. 8, p. 14446, Feb. 2017, doi: 10.1038/ncomms14446.

[10] J. T. Paweska *et al.*, "Lack of Marburg Virus Transmission From Experimentally Infected to Susceptible In-Contact Egyptian Fruit Bats," *J. Infect. Dis.*, vol. 212 Suppl 2, pp. S109-118, Oct. 2015, doi: 10.1093/infdis/jiv132.

[11] M. E. B. Jones *et al.*, "Clinical, Histopathologic, and Immunohistochemical Characterization of Experimental Marburg Virus Infection in A Natural Reservoir Host, the Egyptian Rousette Bat (Rousettus aegyptiacus)," *Viruses*, vol. 11, no. 3, Mar. 2019, doi: 10.3390/v11030214.

[12] J. T. Paweska *et al.*, "Virological and Serological Findings in Rousettus aegyptiacus Experimentally Inoculated with Vero Cells-Adapted Hogan Strain of Marburg Virus," *PLoS One*, vol. 7, no. 9, Sep. 2012, doi: 10.1371/journal.pone.0045479.

[13] B. R. Amman *et al.*, "Oral shedding of Marburg virus in experimentally infected Egyptian fruit bats (Rousettus aegyptiacus)," *J. Wildl. Dis.*, vol. 51, no. 1, pp. 113–124, Jan. 2015, doi: 10.7589/2014-08-198.

[14] M. E. B. Jones *et al.*, "Experimental Inoculation of Egyptian Rousette Bats (Rousettus aegyptiacus) with Viruses of the Ebolavirus and Marburgvirus Genera," *Viruses*, vol. 7, no. 7, pp. 3420–3442, Jun. 2015, doi: 10.3390/v7072779.

[15] A. J. Schuh, B. R. Amman, T. K. Sealy, J. R. Spengler, S. T. Nichol, and J. S. Towner, "Egyptian rousette bats maintain long-term protective immunity against Marburg virus infection despite diminished antibody levels," *Sci Rep*, vol. 7, no. 1, p. 8763, 18 2017, doi: 10.1038/s41598-017-07824-2.

[16] E. M. Leroy *et al.*, "Human Ebola outbreak resulting from direct exposure to fruit bats in Luebo, Democratic Republic of Congo, 2007," *Vector Borne Zoonotic Dis.*, vol. 9, no. 6, pp. 723–728, Dec. 2009, doi: 10.1089/vbz.2008.0167.

[17] A. Marí Saéz *et al.*, "Investigating the zoonotic origin of the West African Ebola epidemic," *EMBO Mol Med*, vol. 7, no. 1, pp. 17–23, Jan. 2015, doi: 10.15252/emmm.201404792.

[18] P. Dovih *et al.*, "Filovirus-reactive antibodies in humans and bats in Northeast India imply zoonotic spillover," *PLOS Neglected Tropical Diseases*, vol. 13, no. 10, p. e0007733, Oct. 2019, doi: 10.1371/journal.pntd.0007733.

[19] X. Pourrut *et al.*, "Large serological survey showing cocirculation of Ebola and Marburg viruses in Gabonese bat populations, and a high seroprevalence of both viruses in Rousettus aegyptiacus," *BMC Infect. Dis.*, vol. 9, p. 159, Sep. 2009, doi: 10.1186/1471-2334-9-159.

[20] J. Yuan, Y. Zhang, J. Li, Y. Zhang, L.-F. Wang, and Z. Shi, "Serological evidence of ebolavirus infection in bats, China," *Virol. J.*, vol. 9, p. 236, Oct. 2012, doi: 10.1186/1743-422X-9-236.

[21] K. J. Olival *et al.*, "Ebola virus antibodies in fruit bats, bangladesh," *Emerging Infect. Dis.*, vol. 19, no. 2, pp. 270–273, Feb. 2013, doi: 10.3201/eid1902.120524.

[22] V. Krähling *et al.*, "Establishment of fruit bat cells (Rousettus aegyptiacus) as a model system for the investigation of filoviral infection," *PLoS Negl Trop Dis*, vol. 4, no. 8, p. e802, Aug. 2010, doi: 10.1371/journal.pntd.0000802.

[23] P. Zhou *et al.,* "Contraction of the type I IFN locus and unusual constitutive expression of IFN-α in bats,"

Proc. Natl. Acad. Sci. U.S.A., vol. 113, no. 10, pp. 2696–2701, Mar. 2016, doi: 10.1073/pnas.1518240113.

[24] N. B. Glennon, O. Jabado, M. K. Lo, and M. L. Shaw, "Transcriptome Profiling of the Virus-Induced Innate Immune Response in Pteropus vampyrus and Its Attenuation by Nipah Virus Interferon Antagonist Functions," *J. Virol.*, vol. 89, no. 15, pp. 7550–7566, Aug. 2015, doi: 10.1128/JVI.00302-15.

[25] S. S. Pavlovich *et al.*, "The Egyptian Rousette Genome Reveals Unexpected Features of Bat Antiviral Immunity," *Cell*, vol. 173, no. 5, pp. 1098-1110.e18, 17 2018, doi: 10.1016/j.cell.2018.03.070.

[26] J. Xie *et al.*, "Dampened STING-Dependent Interferon Activation in Bats," *Cell Host Microbe*, vol. 23, no. 3, pp. 297-301.e4, Mar. 2018, doi: 10.1016/j.chom.2018.01.006.

[27] I. V. Kuzmin *et al.*, "Innate Immune Response of Bat and Human Cells to Filoviruses: Commonalities and Distinctions," *J. Virol.*, Jan. 2017.

[28] S. Becker, M. Spiess, and H. D. Klenk, "The asialoglycoprotein receptor is a potential liver-specific receptor for Marburg virus," *J. Gen. Virol.*, vol. 76 (Pt 2), pp. 393–399, Feb. 1995, doi: 10.1099/0022-1317-76-2-393.

[29] I. Kushner, "The phenomenon of the acute phase response," *Ann. N. Y. Acad. Sci.*, vol. 389, pp. 39–48, 1982, doi: 10.1111/j.1749-6632.1982.tb22124.x.

[30] C. Gabay and I. Kushner, "Acute-phase proteins and other systemic responses to inflammation," *N. Engl. J. Med.*, vol. 340, no. 6, pp. 448–454, Feb. 1999, doi: 10.1056/NEJM199902113400607.

[31] I. Kushner, "Acute phase reactants," *UpToDate*. https://www.uptodate.com/contents/acute-phase-reactants.

[32] J. Gauldie, C. Richards, D. Harnish, P. Lansdorp, and H. Baumann, "Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells," *Proc. Natl. Acad. Sci. U.S.A.*, vol. 84, no. 20, pp. 7251–7255, Oct. 1987, doi: 10.1073/pnas.84.20.7251.

[33] H. J. Moshage, J. A. Janssen, J. H. Franssen, J. C. Hafkenscheid, and S. H. Yap, "Study of the molecular mechanism of decreased liver synthesis of albumin in inflammation," *J. Clin. Invest.*, vol. 79, no. 6, pp. 1635–1641, Jun. 1987, doi: 10.1172/JCI113000.

[34] E. Dvash, M. Har-Tal, S. Barak, O. Meir, and M. Rubinstein, "Leukotriene C_4 is the major trigger of stress-induced oxidative DNA damage," *Nature Communications*, vol. 6, p. 10112, Dec. 2015, doi: 10.1038/ncomms10112.

[35] M. Noris and G. Remuzzi, "Overview of Complement Activation and Regulation," *Semin Nephrol*, vol. 33, no. 6, pp. 479–492, Nov. 2013, doi: 10.1016/j.semnephrol.2013.08.001.

[36] R. N. Germain, "T-cell development and the CD4–CD8 lineage decision," *Nat Rev Immunol*, vol. 2, no. 5, Art. no. 5, May 2002, doi: 10.1038/nri798.

[37] M. D. Knutson, "Iron transport proteins: Gateways of cellular and systemic iron homeostasis," *J. Biol. Chem.*, vol. 292, no. 31, pp. 12735–12743, 04 2017, doi: 10.1074/jbc.R117.786632.

[38] "Fraction of iron in body that is present in h - Human Homo sapiens - BNID 104009." https://bionumbers.hms.harvard.edu/bionumber.aspx?s=n&v=3&id=104009 (accessed Mar. 15, 2021).

[39] A. M. Prentice *et al.*, "Hepcidin is the major predictor of erythrocyte iron incorporation in anemic African children," *Blood*, vol. 119, no. 8, pp. 1922–1928, Feb. 2012, doi: 10.1182/blood-2011-11-391219.

[40] J. Przybyszewska and E. Żekanowska, "The role of hepcidin, ferroportin, HCP1, and DMT1 protein in iron absorption in the human digestive tract," *Prz Gastroenterol*, vol. 9, no. 4, pp. 208–213, 2014, doi: 10.5114/pg.2014.45102.

[41] Y. Kohgo, K. Ikuta, T. Ohtake, Y. Torimoto, and J. Kato, "Body iron metabolism and pathophysiology of iron overload," *Int J Hematol*, vol. 88, no. 1, pp. 7–15, 2008, doi: 10.1007/s12185-008-0120-5.

[42] M. Wessling-Resnick, "Crossing the Iron Gate: Why and How Transferrin Receptors Mediate Viral Entry," *Annu. Rev. Nutr.*, vol. 38, pp. 431–458, 21 2018, doi: 10.1146/annurev-nutr-082117-051749.

[43] G. Gao and Y.-Z. Chang, "Mitochondrial ferritin in the regulation of brain iron homeostasis and neurodegenerative diseases," *Front Pharmacol*, vol. 5, Feb. 2014, doi: 10.3389/fphar.2014.00019.

[44] E. M. Conway, "Complement-coagulation connections," *Blood Coagulation & Fibrinolysis*, vol. 29, no. 3, p. 243, Apr. 2018, doi: 10.1097/MBC.0000000000000720.

[45] J. Hoover-Plow, "Does plasmin have anticoagulant activity?," *Vasc Health Risk Manag*, vol. 6, pp. 199–205, Apr. 2010, doi: 10.2147/vhrm.s9358.

[46] W. Miesbach, "Pathological Role of Angiotensin II in Severe COVID-19," *TH Open*, vol. 4, no. 2, pp. e138–e144, Apr. 2020, doi: 10.1055/s-0040-1713678.

[47] T. Wang, H. Liu, G. Lian, S.-Y. Zhang, X. Wang, and C. Jiang, "HIF1α-Induced Glycolysis Metabolism Is Essential to the Activation of Inflammatory Macrophages," *Mediators Inflamm.*, vol. 2017, p. 9029327, 2017, doi: 10.1155/2017/9029327.

[48] E. L. Mills and L. A. O'Neill, "Reprogramming mitochondrial metabolism in macrophages as an anti-inflammatory signal," *Eur. J. Immunol.*, vol. 46, no. 1, pp. 13–21, Jan. 2016, doi: 10.1002/eji.201445427.

[49] V. Nizet and R. S. Johnson, "Interdependence of hypoxic and innate immune responses," *Nat. Rev. Immunol.*, vol. 9, no. 9, pp. 609–617, Sep. 2009, doi: 10.1038/nri2607.

[50] C. M. Krawczyk *et al.*, "Toll-like receptor-induced changes in glycolytic metabolism regulate dendritic cell activation," *Blood*, vol. 115, no. 23, pp. 4742–4749, Jun. 2010, doi: 10.1182/blood-2009-10-249540.

[51] G. M. Tannahill *et al.*, "Succinate is an inflammatory signal that induces IL-1β through HIF-1α," *Nature*, vol. 496, no. 7444, pp. 238–242, Apr. 2013, doi: 10.1038/nature11986.

[52] Z. Tan *et al.*, "Pyruvate dehydrogenase kinase 1 participates in macrophage polarization via regulating glucose metabolism," *J. Immunol.*, vol. 194, no. 12, pp. 6082–6089, Jun. 2015, doi: 10.4049/jimmunol.1402469.

[53] C. J. Ferrante *et al.*, "The adenosine-dependent angiogenic switch of macrophages to an M2-like phenotype is independent of interleukin-4 receptor alpha (IL-4Rα) signaling," *Inflammation*, vol. 36, no. 4, pp. 921–931, Aug. 2013, doi: 10.1007/s10753-013-9621-3.

[54] R. Imamura and K. Matsumoto, "Hepatocyte growth factor in physiology and infectious diseases," *Cytokine*, vol. 98, pp. 97–106, 2017, doi: 10.1016/j.cyto.2016.12.025.

[55] C. Atri, F. Z. Guerfali, and D. Laouini, "Role of Human Macrophage Polarization in Inflammation during Infectious Diseases," *Int J Mol Sci*, vol. 19, no. 6, Jun. 2018, doi: 10.3390/ijms19061801.

[56] L. Parisi *et al.*, "Macrophage Polarization in Chronic Inflammatory Diseases: Killers or Builders?," *J Immunol Res*, vol. 2018, Jan. 2018, doi: 10.1155/2018/8917804.

[57] L. Helming, "Inflammation: Cell Recruitment versus Local Proliferation," *Current Biology*, vol. 21, no. 14, pp. R548–R550, Jul. 2011, doi: 10.1016/j.cub.2011.06.005.

[58] S. J. Jenkins *et al.*, "Local macrophage proliferation, rather than recruitment from the blood, is a signature of TH2 inflammation," *Science*, vol. 332, no. 6035, pp. 1284–1288, Jun. 2011, doi: 10.1126/science.1204351.

[59] M. P. Murphy, "Rerouting metabolism to activate macrophages," *Nat Immunol*, pp. 1–3, Aug. 2019, doi: 10.1038/s41590-019-0455-5.

[60] C. Werno *et al.*, "Knockout of HIF-1α in tumor-associated macrophages enhances M2 polarization and attenuates their pro-angiogenic responses," *Carcinogenesis*, vol. 31, no. 10, pp. 1863–1872, Oct. 2010, doi: 10.1093/carcin/bgq088.

[61] R. Agoro, M. Taleb, V. F. J. Quesniaux, and C. Mura, "Cell iron status influences macrophage polarization," *PLOS ONE*, vol. 13, no. 5, p. e0196921, May 2018, doi: 10.1371/journal.pone.0196921.

[62] D. C. P. Rossi and G. S. Deepe, "Type I Interferons Rule with an Iron Fist," *Cell Host & Microbe*, vol. 27, no. 3, pp. 317–319, Mar. 2020, doi: 10.1016/j.chom.2020.02.007.

[63] C. S. Ng, H. Kato, and T. Fujita, "Fueling Type I Interferonopathies: Regulation and Function of Type I Interferon Antiviral Responses," *Journal of Interferon & Cytokine Research*, vol. 39, no. 7, pp. 383–392, Mar. 2019, doi: 10.1089/jir.2019.0037.

[64] M. Wadm, Ec. 15, 2020, and 5:00 Pm, "COVID-19 is 10 times deadlier for people with Down syndrome, raising calls for early vaccination," *Science | AAAS*, Dec. 15, 2020. https://www.sciencemag.org/news/2020/12/covid-19-10-times-deadlier-people-down-syndrome-raising-calls-early-vaccination (accessed Dec. 17, 2020).

[65] K. D. Sullivan *et al.*, "Trisomy 21 consistently activates the interferon response," *Elife*, vol. 5, Jul. 2016, doi: 10.7554/eLife.16220.

[66] J. T. Paweska, N. Storm, A. A. Grobbelaar, W. Markotter, A. Kemp, and P. Jansen van Vuren, "Experimental Inoculation of Egyptian Fruit Bats (Rousettus aegyptiacus) with Ebola Virus," *Viruses*, vol. 8, no. 2, Jan. 2016, doi: 10.3390/v8020029.

[67] Y. Wu, L. A. Potempa, D. El Kebir, and J. G. Filep, "C-reactive protein and inflammation: conformational changes affect function," *Biol. Chem.*, vol. 396, no. 11, pp. 1181–1197, Nov. 2015, doi: 10.1515/hsz-2015-0149.

[68] T. W. Du Clos, "C-reactive protein as a regulator of autoimmunity and inflammation," *Arthritis Rheum.*, vol. 48, no. 6, pp. 1475–1477, Jun. 2003, doi: 10.1002/art.11025.

[69] A. J. Schuh *et al.*, "Antibody-Mediated Virus Neutralization Is Not a Universal Mechanism of Marburg, Ebola, or Sosuga Virus Clearance in Egyptian Rousette Bats," *J. Infect. Dis.*, vol. 219, no. 11, pp. 1716–1721, May 2019, doi: 10.1093/infdis/jiy733.

[70] A. K. McElroy *et al.*, "Human Ebola virus infection results in substantial immune activation," *Proc. Natl. Acad. Sci. U.S.A.*, vol. 112, no. 15, pp. 4719–4724, Apr. 2015, doi: 10.1073/pnas.1502619112.

[71] C. Dahlke *et al.*, "Comprehensive Characterization of Cellular Immune Responses Following Ebola Virus Infection," *J. Infect. Dis.*, vol. 215, no. 2, pp. 287–292, 15 2017, doi: 10.1093/infdis/jiw508.

[72] S. Reynard *et al.*, "Immune parameters and outcomes during Ebola virus disease," *JCI Insight*, vol. 4, no. 1, Jan. 2019, doi: 10.1172/jci.insight.125106.

[73] T. G. Ksiazek *et al.*, "Clinical virology of Ebola hemorrhagic fever (EHF): virus, virus antigen, and IgG and IgM antibody findings among EHF patients in Kikwit, Democratic Republic of the Congo, 1995," *J Infect Dis*, vol. 179 Suppl 1, pp. S177-187, Feb. 1999, doi: 10.1086/514321.

[74] X. Liu *et al.*, "Transcriptomic signatures differentiate survival from fatal outcomes in humans infected with Ebola virus," *Genome Biology*, vol. 18, no. 1, p. 4, Jan. 2017, doi: 10.1186/s13059-016-1137-3.

[75] P. Younan, P. Ramanathan, J. Graber, F. Gusovsky, and A. Bukreyev, "The Toll-Like Receptor 4 Antagonist Eritoran Protects Mice from Lethal Filovirus Challenge," *MBio*, vol. 8, no. 2, 25 2017, doi: 10.1128/mBio.00226-17.

[76] A. K. McElroy *et al.*, "Ebola hemorrhagic Fever: novel biomarker correlates of clinical outcome," *J. Infect. Dis.*, vol. 210, no. 4, pp. 558–566, Aug. 2014, doi: 10.1093/infdis/jiu088.

[77] A. L. Rasmussen *et al.*, "Host genetic diversity enables Ebola hemorrhagic fever pathogenesis and resistance," *Science*, vol. 346, no. 6212, pp. 987–991, Nov. 2014, doi: 10.1126/science.1259595.

[78] S. A. Jones and C. A. Hunter, "Is IL-6 a key cytokine target for therapy in COVID-19?," *Nature Reviews Immunology*, pp. 1–3, Apr. 2021, doi: 10.1038/s41577-021-00553-8.

[79] C. Salama *et al.*, "Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia," *New England Journal of Medicine*, vol. 384, no. 1, pp. 20–30, Jan. 2021, doi: 10.1056/NEJMoa2030340.

[80] D. S. Fedson, "A Practical Treatment for Patients With Ebola Virus Disease," *J Infect Dis*, vol. 211, no. 4, pp. 661–662, Feb. 2015, doi: 10.1093/infdis/jiu474.

[81] D. G. Cacione, C. R. Macedo, and J. C. Baptista-Silva, "Pharmacological treatment for Buerger's disease," *Cochrane Database of Systematic Reviews*, no. 3, 2016, doi: 10.1002/14651858.CD011033.pub3.

[82] C. G. Albariño *et al.*, "Development of a reverse genetics system to generate recombinant Marburg virus derived from a bat isolate," *Virology*, vol. 446, no. 1–2, pp. 230–237, Nov. 2013, doi: 10.1016/j.virol.2013.07.038.

[83] Z. J. Whitfield *et al.*, "Species-Specific Evolution of Ebola Virus during Replication in Human and Bat Cells," *Cell Rep*, vol. 32, no. 7, p. 108028, Aug. 2020, doi: 10.1016/j.celrep.2020.108028.

[84] D. Jebb *et al.*, "Six new reference-quality bat genomes illuminate the molecular basis and evolution of bat adaptations," *bioRxiv*, p. 836874, Nov. 2019, doi: 10.1101/836874.

[85] N. L. Bray, H. Pimentel, P. Melsted, and L. Pachter, "Near-optimal probabilistic RNA-seq quantification," *Nature Biotechnology*, vol. 34, no. 5, pp. 525–527, May 2016, doi: 10.1038/nbt.3519.

[86] M. Hölzer *et al.*, "Differential transcriptional responses to Ebola and Marburg virus infection in bat and human cells," *Scientific Reports*, vol. 6, p. 34589, Oct. 2016, doi: 10.1038/srep34589.

[87] "The Gene Ontology Resource: 20 years and still GOing strong," *Nucleic Acids Res*, vol. 47, no. D1, pp. D330–D338, Jan. 2019, doi: 10.1093/nar/gky1055.

Table 1. Acute phase proteins in livers respond strongly to inflammatory cytokines

Positive APPs	MARV (fold change)	EBOV (fold change)	Uninfected (tpm)
Serum Amyloid A 1 (SAA1)	21X	3X	6858
Serum Amyloid A 2 (SAA2)	39X	5X	440
Ceruloplasmin (CP)	10X	5X	129
HAMP*	8.5X	10X	211
Orosomucoid 2 Alpha1-Acid glycoprotein (ORM2*)	34X	47X	14
Microsomal Glutathione S-Transferase (MGST1)	4X	4X	277
MGST2*	11X	16X	5.5
MGST3	0.4X	0.7X	461
Fibrinogen (FGA)	2X	1X	1277
Fibrinogen (FGB)	2X	1X	9007
Fibrinogen (FGG)	1X	1X	6070
C4B	2X	1X	1015
C3P1	6X	1X	31
Haptoglobin (HP)	1.1X	0.7X	15906
Alpha2-Macroglobulin (A2M)	1.3X	1X	409
C-reactive protein (CRP)	N/A	N/A	N/A
Negative APPs			
Albumin (ALB)	0.6X	1.2X	51400
Transferrin (TF)	1X	1X	22856
Transthyretin (TTR)	2X	2X	1
Retinol Binding protein (RBP4)	0.5X	0.6X	3107

Basal expression levels in tpm units are shown in the Uninfected column. The fold change upon infection is shown in the MARV and EBOV columns. SAA1/2, CP were highly expressed in livers normally and also get upregulated by filovirus infections, with a greater upregulation by MARV. ORM2, MGST2 are upregulated, but from a low basal expression level. CRP, used as a marker for acute phase response in humans, is highlighted in gray to emphasize that it does not appear to be expressed in this bat species and might be absent in bats altogether. TF was highly expressed in all samples, but the expression did not change in response to filoviral infections, while TTR was not expressed in any of the samples. A similar inflammation was detected in the liver upon both MARV and EBOV infection, despite the lack of viral transcripts in the liver of EBOV infected animals. *Bat genes divergent from their respective human homologs.

Fig. 1. Infection of bats with filoviruses MARV and EBOV. A – C. Time course after infection for weight (A), temperature (B) and viral RNA specific for the NP gene in total RNA extracted from whole blood. Animals were euthanized 48 h after first viremic time point. Tissue viral loads in panels **D**, **E** were determined by plaque assay on Vero E6 cells. Note that MARV bat 2 sensor failed. **F.** Histopathology and viral antigen in filovirus infected organs showing: (i) Lack of significant histopathological lesions in mammary tissue from MARV-infected bat 1, (ii) Lack of significant histopathological lesions within the interstitium of the epididymis from MARV-infected bat 3, (iii) IHC detection of MARV antigen within the interstitium of the glandular structures of the mammary gland from MARV-infected bat 1 (red pigment, arrows), (iv) IHC detection of MARV antigen within the interstitium of the epididymis from MARV-infected bat 3 (red pigment, arrows), (v) EBOV-infected bat 1 liver with marked histopathological changes, including cytoplasmic and nuclear inclusions (arrows), (vi) EBOV-infected bat 2 liver displaying a less dramatic presentation compared to bat 1 (arrows), (vii) IHC detection of EBOV antigen in the liver of EBOV-infected bat 1 (arrows), (viii) IHC detection of EBOV antigen in EBOV-infected bat 1 liver (an arrow).

Fig. 2. Changes in gene expression patterns in livers following infections OF bats with MARV and EBOV: upset plot. Uninf*:* Uninfected bat livers, EBOV: EBOV-infected bat livers, MARV: MARV-infected bat livers. Each row in the lower panel represents a set with the corresponding bars at the lower left representing membership in the sets. There are six sets of genes, e.g., EBOV/Uninf comprises of genes at least 2-fold upregulated in EBOV infection, compared to the uninfected samples, while Uninf/EBOV is genes at least 2-fold down regulated in EBOV samples compared to the uninfected samples. The vertical blue lines with bulbs represent sets of intersections with the main bar plot (top) is number of genes unique to that intersection, so the total belonging to the set Uninf/EBOV, as an example, is a sum of the numbers in all sets that have Uninf/EBOV as a member (41+203+6+31=281). The last bar with 6 members is the set of genes common to EBOV/MARV, EBOV/Uninf and MARV/Uninf. Many more genes responded to MARV infection than to EBOV infection (1,897 genes in MARV/Uninf versus 429 genes in EBOV/Uninf). The much greater number of MARV-specific (MARV/EBOV) genes than EBOV-specific (EBOV/MARV) genes is most likely due to the different levels of infections; when the samples were collected, EBOV was cleared, while MARV was in the process of being cleared. Some differences between MARV and EBOV are likely due to interferon antagonism differentially mediated by VP40 and VP35 in MARV and VP40 and VP24 in EBOV.

A Liver

B Spleen

Fig. 3. Multidimensional scaling (MDS) plots of the merged gene expression data from livers of MARV-infected, EBOV-infected and uninfected bats. There is a clear separation between MARV infections, EBOV infections and the uninfected sample both in livers (**A**) and spleens (**B**). Virus-specific signatures were also detected in kidneys (**Fig. S1**), implying the response to filovirus infections extends to the whole animal. Panel A shows liver from an uninfected bat (the blue dot in lower right) that seems to be different from the other two samples from uninfected bats, as also seen in the correlations shown in **Table ST9**. The different pattern for this bat may be explained by its reaction to some stimulus, either an infection or an injury; the animal has been excluded from the downstream analysis.

18443 Genes
Bat-human divergence

2439 Genes
Expression in liver

264 Genes
↑↓ **Regulation**

151 Genes
Pathways

Mitochondria (20)	Vascular (19)	Macrophage (13)
Innate (16)	T-cells (4)	Apoptosis (15)
Inflammation (10)	Complement (2)	Metabolism (8)

Fig. 4. Analysis of evolutionary divergent genes as an approach for understanding the response to filovirus infections. The approach used in this study was based on identification of pathways relevant to the bat's resilience to filoviral infections. It was assumed that the most homologous genes perform similar functions in bats and humans, and bat genes evolutionarily divergent from their human homologs have a greater probability of having altered functions. The divergent genes were identified using homology detected through BLAST alignments of the corresponding sequences from the two species. Of these, genes differentially expressed in livers of infected bats were identified. The pathways they influence were explored to evaluate the systemic response to filovirus infections in bats and to identify key differences from the responses in humans. Blood pressure, coagulation and iron homeostasis pathways were altered most prominently. The analysis demonstrated changes in glycolysis, which is controlled by hypoxia, which shift the balance of macrophage activation from the M1 (proinflammatory) to the M2 (anti-inflammatory) state. These changes create a pro-inflammatory state that modulate the response and allows the adaptive immune system to clear the infection early, and anti-inflammatory response late. The identified pathways demonstrated incomplete activation of the complement system, likely compromising the antibody response, but strong activation of T cell response which is likely to play a major role in clearing the infection. The identified pathways are interconnected, as shown in **Fig. 6**.

Fig. 5. Differential expression of genes belonging to the indicated pathways by MARV and EBOV infections in livers of bats. The **c**olumns show differentially expressed genes from livers of three MARV-infected bats, three EBOV-infected bats and two uninfected bats. The values are log$_2$ of the fpm values, with the mean values from uninfected animals subtracted. Broadly, the majority of the genes are in a quiescent, low expression state in the uninfected samples, and get stimulated upon infections, with greater effects in the case of MARV and intermediate effects in case of EBOV. APP: acute phase response proteins; Compl: complement; Hyp: hypoxia related genes; M1 and M2: genes specific to M1 or M2 macrophages, respectively; M1M2: genes common to M1 and M2 macrophages; Mito: genes expressed in mitochondria; Tcells: genes expressed in T cells; Tissue: genes involved in tissue regeneration and apoptosis; BP: genes involved in regulation of blood pressure; ISG: interferon stimulated genes; IRON: genes involved in iron homeostasis; COAG: genes involved in coagulation. A * after a gene name indicates that the bat version is divergent from its human counterpart. Alternate blocks of gene names are colored black/blue to allow easy visual distinction of the blocks. **Fig. S2A** and **S2B** show corresponding figures for kidneys and spleens.

Fig. 6. A model of bat response to filovirus infections. Interferon stimulated genes (ISG, Fig. 5,S2,S3) cause inflammation, which triggers the acute phase response (APR, Table 1, Fig. 5), leading to a cascade of reactions affecting regulation of HAMP (iron, Fig. 5,S6), coagulation (Fig. 5, S7, S8), blood pressure (Fig. 5, S7) and stimulating M1 macrophages (Fig. 5, S5, S10, S11). The pro-inflammatory M1 macrophages phagocytose infected cells and promote apoptosis. Over the course of infection, M1 macrophages get converted to anti-inflammatory M2 macrophages. This process is accompanied by activation of fatty acid oxidation and mitochondrial activity, which are the hallmarks of the M2 macrophage responses (Fig. 5, S10, S11). On the other hand, activation of the complement system is incomplete, potentially leading to a reduced antibody activity (Fig. 5, S5B). Furthermore, filovirus infections were accompanied by downregulation of blood pressure (Fig. 5, S7) and the coagulation system (Fig. 5, S9). The infections are also accompanied by shift in genes regulating iron homeostasis (Fig. 5,S7, S8, S9, S11), which are generally consistent with a greater activation of the M2 macrophage response in case of EBOV infections. The infections resulted in activation of CD8[+] T cell response (Fig. S5C), presumably contributing to clearance of the infections. The dotted boundaries indicate at pathways which responded to filovirus infections in bats differently from human.